GCC will operate dialysis centers in Kolathur and Kondithope.
The Greater Chennai Corporation (GCC) will oversee and maintain two dialysis centers being constructed by the Chennai Metropolitan Development Authority (CMDA) in Kolathur and Kondithope. The centers will provide blood purification services, and the GCC has proposed covering the beneficiaries under the Chief Minister’s Comprehensive Health Insurance Scheme (CMCHIS). Until the scheme is formally approved, the GCC will bear the dialysis treatment costs, which will be operated by Apollo Hospitals.
The Kolathur center, located in the Thiru-Vi-Ka Nagar zone, will be a multi-story facility offering integrated services. The center will have an artificial limb center on the first floor, a physical training center on the second floor, a blood purification unit for dialysis procedures on the third floor, and patient amenities on the fourth floor. Similarly, the Kondithope facility, located in the Royapuram zone, will function as a comprehensive rehabilitation center with similar facilities.
The decision to establish these centers was made in a meeting chaired by CMDA Minister PK Sekarbabu in September. The meeting decided that while the CMDA would establish the facilities, the GCC would handle their operation and maintenance. The GCC’s joint commissioner (Health) and the North Chennai regional deputy commissioner were also present at the meeting.
The construction of these dialysis centers aims to provide accessible and affordable healthcare services to the residents of Chennai. The GCC’s decision to bear the treatment costs until the CMCHIS is approved ensures that the beneficiaries can receive the necessary treatment without any delays. The comprehensive rehabilitation centers will also provide a range of services, including artificial limb fitting, physical training, and patient amenities, making them a one-stop destination for patients requiring dialysis and rehabilitation services. Overall, the establishment of these centers is expected to improve the healthcare infrastructure in Chennai and provide better services to the residents.
Aurobindo Pharma Pushes Back Deadline to Purchase 26% Stake in Swarnaakshu Solar
Aurobindo Pharma has extended the timeline to acquire a 26% stake in Swarnaakshu Solar, a solar power company. The acquisition is part of Aurobindo Pharma’s strategy to diversify its business and invest in renewable energy.
The company had initially planned to complete the acquisition by a certain deadline, but it has now been extended due to various reasons. The extension of the timeline is expected to give Aurobindo Pharma more time to complete the necessary formalities and regulatory approvals.
Aurobindo Pharma is one of the leading pharmaceutical companies in India, and its decision to invest in Swarnaakshu Solar marks a significant departure from its core business. The company has been looking to diversify its portfolio and reduce its dependence on the pharmaceutical sector.
Swarnaakshu Solar is a solar power company that specializes in the development and operation of solar power plants. The company has a strong presence in the Indian renewable energy market and has developed several solar power projects across the country.
The acquisition of a 26% stake in Swarnaakshu Solar is expected to give Aurobindo Pharma a significant foothold in the renewable energy sector. The company plans to use the investment to expand its presence in the solar power market and to reduce its carbon footprint.
The extension of the timeline to acquire a stake in Swarnaakshu Solar is not expected to have a significant impact on Aurobindo Pharma’s financial performance in the short term. However, the investment is expected to provide long-term benefits to the company and help it to achieve its sustainability goals.
Aurobindo Pharma’s decision to invest in Swarnaakshu Solar is part of a larger trend of pharmaceutical companies diversifying their business and investing in renewable energy. The investment is expected to help the company to reduce its dependence on fossil fuels and to achieve its sustainability goals.
Overall, the extension of the timeline to acquire a stake in Swarnaakshu Solar is a positive development for Aurobindo Pharma and marks a significant step forward in the company’s strategy to diversify its business and invest in renewable energy. The investment is expected to provide long-term benefits to the company and help it to achieve its sustainability goals.
Delhi High Court bars Dr Reddy’s from producing VENUSIA sunscreens bearing the SUN logo.
The Delhi High Court has issued an interim order restraining Dr. Reddy’s Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word “SUN”. The court’s decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy’s is infringing on its trademark rights.
Glenmark Pharmaceuticals had launched its own sunscreen product, SUNSTAR, in 2018, and had obtained a trademark registration for the mark “SUN” in relation to sunscreen products. The company claims that Dr. Reddy’s use of the word “SUN” on its VENUSIA sunscreens is likely to cause confusion among consumers and dilute the distinctiveness of Glenmark’s trademark.
The Delhi High Court has agreed with Glenmark’s arguments, observing that Dr. Reddy’s use of the word “SUN” on its products is likely to cause confusion among consumers, who may mistakenly believe that the VENUSIA sunscreens are connected to Glenmark’s SUNSTAR product. The court has therefore restrained Dr. Reddy’s from using the word “SUN” on its VENUSIA sunscreens, pending the outcome of the lawsuit.
The court’s order is a significant setback for Dr. Reddy’s, which had launched its VENUSIA sunscreens with the SUN label in an attempt to capitalize on the popularity of sunscreens in the Indian market. The company will now have to rebrand its products and remove the SUN label, which could result in significant losses and damage to its reputation.
The lawsuit highlights the importance of trademark protection in the pharmaceutical industry, where companies invest heavily in building their brands and trademarks. The Delhi High Court’s decision demonstrates that courts will take a strict view of trademark infringement, particularly in cases where there is a likelihood of confusion among consumers.
The case will now proceed to trial, where Glenmark will have to prove that Dr. Reddy’s use of the word “SUN” on its VENUSIA sunscreens constitutes trademark infringement. If the court ultimately rules in favor of Glenmark, Dr. Reddy’s could face significant damages and penalties for its alleged infringement. The case is being closely watched by the pharmaceutical industry, which is keen to see how the courts will interpret trademark laws in cases of alleged infringement.
Tragedy strikes in Bengaluru as 26-year-old Biocon staff member takes fatal leap from 5th floor of office building.
A 26-year-old employee of Biocon, a biopharmaceutical company, jumped to his death from the 5th floor of the company’s office building in Bengaluru, India. The incident occurred on a recent day, and the police are currently investigating the circumstances surrounding the death.
According to reports, the employee, whose identity has not been disclosed, was working in the research and development department of Biocon. He was a resident of Bengaluru and had been working with the company for several years. The police have stated that they are reviewing CCTV footage and speaking with colleagues and family members to determine the cause of the incident.
The incident has sent shockwaves through the company, with many colleagues and friends expressing their condolences on social media. Biocon has released a statement expressing its sadness and shock at the incident, and has offered support to the employee’s family.
The police have ruled out any foul play in the incident, and are treating it as a case of suicide. However, they are still investigating the circumstances that led to the employee’s death, including any potential work-related stress or personal issues.
This incident highlights the growing concern of mental health and stress in the corporate world, particularly in the tech and biotech industries. Many employees in these industries face high levels of stress and pressure to perform, which can take a toll on their mental health. Companies are increasingly recognizing the importance of providing support and resources to employees to manage stress and promote mental well-being.
Biocon has a reputation for being a supportive and employee-friendly company, with a range of initiatives and programs in place to promote employee well-being. However, this incident highlights the need for companies to do more to support employees who may be struggling with mental health issues.
The incident is also a reminder of the importance of seeking help and support when struggling with mental health issues. If you or someone you know is struggling with mental health issues, there are resources available to help. The National Institute of Mental Health and Neuro Sciences (NIMHANS) has a 24-hour helpline that provides support and counseling services. Additionally, many companies have employee assistance programs (EAPs) that provide confidential counseling and support services to employees.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.